Description

Visionary senior executive with a track record of transforming organisations, driving commercial success, and leading global business strategies in cardiometabolic/renal, autoimmune diseases, oncology and hematology markets.

Proven ability to deliver above-market growth, scale global franchises, and manage multi billion-dollar portfolios with full P&L accountability. Adept at launching blockbuster therapies,

navigating complex market ecosystems, and leading high-performing team.

Expert in general management and commercial strategy, global franchise leadership, lifecycle management and ecosystem transformation, cross-functional leadership and talent development, P&L management and business growth.

Domaines d’expertise

Langues

Allemand
Bilingue ou natif
Anglais
Bilingue ou natif
Français
Capacité professionnelle limitée

Préférences en matière de lieu de travail

Accepte de travailler sur site

Zürich (jusqu’à 50 km)

Novo Nordisk A/S
Interim Corporate Vice President, Diabetes Commercial Unit
mai 2022 - août 2022 (3 mois)
Denmark
Led global diabetes business unit, overseeing 5 Vice Presidents and defining strategy for GLP-1 and insulin portfolios

Drove market expansion strategies and prepared for first weekly insulin launch
Product Launch Strategy New product launch Change and Transformation Management Global Marketing Portfolio Strategy
Novo Nordisk A/S
Project Vice President Global Commercial - Oral Semaglutide
INDUSTRIE PHARMACEUTIQUE
octobre 2021 - avril 2025 (3 ans et 6 mois)
Denmark
Leading Global Project Team for Oral Semaglutide, focusing on long-term life cycle strategy and P&L accountability

Managing cross-functional teams of 15+ senior leaders and oversee multi-million dollar budgets to expand market leadership

Spearhead global ecosystem strategies, shaping treatment goals, drug development, supply chain and commercialisation
Ecosystem Development Product Launch Strategy Global Marketing Growth Strategies Supply-Chain Management
Novo Nordisk A/S
VP Global Marketing Ozempic & Victoza
INDUSTRIE PHARMACEUTIQUE
mars 2020 - janvier 2021 (10 mois)
Denmark
Strategic lead of the injectable GLP-1 franchise, achieving unprecedented growth, market dominance and positioning Ozempic as an iconic brand

Strategic lead of core markets, and 15 senior marketeers Established company's cardiorenal market strategy
Product Launch Strategy Global Marketing New product launch Growth Strategies market expansion